Abstract
The paradigm of empiric treatment for advanced or metastatic non-small cell carcinoma of the lung (A-NSCLC) has been challenged in recent years, with an increasing emphasis on personalizing current therapies and utilizing new therapies that target the drivers of carcinogenesis. As more systemic therapies become available, decisions regarding the optimal type of therapy, timing and duration of treatment are becoming increasingly complex. Clinicians involved in the care of patients with lung cancer may wish to be kept up-to-date regarding the current approaches to treatment. Herein we provide an overview of the current systemic therapies for A-NSCLC, discussing evidence-based approaches to firstline, second-line and maintenance treatment. An outline of the pharmacology of the major classes of active drugs is given, and key evidence is outlined and organized by line of treatment. The characteristics of the target populations for treatment are discussed, along with the optimal combination and timing of therapy.
Keywords: Chemotherapy, bevacizumab, EGFR inhibitors, metastatic, pemetrexed, pharmacology, review, non-small cell carcinoma
Current Respiratory Medicine Reviews
Title: An Overview: Current Systemic Therapies for Advanced Non-Small Cell Lung Cancer
Volume: 7 Issue: 5
Author(s): Michael Ong and Mark D. Vincent
Affiliation:
Keywords: Chemotherapy, bevacizumab, EGFR inhibitors, metastatic, pemetrexed, pharmacology, review, non-small cell carcinoma
Abstract: The paradigm of empiric treatment for advanced or metastatic non-small cell carcinoma of the lung (A-NSCLC) has been challenged in recent years, with an increasing emphasis on personalizing current therapies and utilizing new therapies that target the drivers of carcinogenesis. As more systemic therapies become available, decisions regarding the optimal type of therapy, timing and duration of treatment are becoming increasingly complex. Clinicians involved in the care of patients with lung cancer may wish to be kept up-to-date regarding the current approaches to treatment. Herein we provide an overview of the current systemic therapies for A-NSCLC, discussing evidence-based approaches to firstline, second-line and maintenance treatment. An outline of the pharmacology of the major classes of active drugs is given, and key evidence is outlined and organized by line of treatment. The characteristics of the target populations for treatment are discussed, along with the optimal combination and timing of therapy.
Export Options
About this article
Cite this article as:
Ong Michael and D. Vincent Mark, An Overview: Current Systemic Therapies for Advanced Non-Small Cell Lung Cancer, Current Respiratory Medicine Reviews 2011; 7 (5) . https://dx.doi.org/10.2174/157339811797189759
DOI https://dx.doi.org/10.2174/157339811797189759 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of Active Drug Transporters in Refractory Multiple Myeloma
Current Topics in Medicinal Chemistry Preface
Recent Patents on Anti-Cancer Drug Discovery Subject Index To Volume 6
Current Molecular Medicine Lipid based Nanocapsules: A Multitude of Biomedical Applications
Current Pharmaceutical Biotechnology Functions of S100 Proteins
Current Molecular Medicine TEM8 Targeted Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Approaches to Improve Efficiency of Dendritic Cell-based Therapy of High Grade Gliomas
Current Pharmaceutical Design Clinical Applications of Gene Therapy in Head and Neck Cancer
Current Gene Therapy P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives
Current Cancer Drug Targets Recent Advances in Therapeutic Peptides for Breast Cancer Treatment
Current Protein & Peptide Science Recent Developments of Platinum-based Anticancer Drugs- Detection and Analysis in Biological Samples
Current Organic Chemistry Hematopoietic Growth Factors Support in the Elderly Cancer Patients Treated with Antiblastic Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Iron Chelators in Medicinal Applications - Chemical Equilibrium Considerations in Pharmaceutical Activity
Current Medicinal Chemistry Hybrid Bioactive Heterocycles as Potential Antimicrobial Agents: A Review
Mini-Reviews in Medicinal Chemistry A Common Biological Mechanism in Cancer and Alzheimers Disease?
Current Alzheimer Research Pentapeptides as Minimal Functional Units in Cell Biology and Immunology
Current Protein & Peptide Science Nucleosides with Modified Sugar Ring: Synthesis and Biological Activities
Current Organic Chemistry Paullones as Inhibitors of Protein Kinases
Current Topics in Medicinal Chemistry Cdc20: A Potential Novel Therapeutic Target for Cancer Treatment
Current Pharmaceutical Design A Review of Ruthenium Complexes Activities on Breast Cancer Cells
Mini-Reviews in Medicinal Chemistry